Incannex Healthcare (IXHL) Research & Development (2022 - 2026)

Incannex Healthcare has disclosed Research & Development across 5 years of filings, most recently posting $321000.0 for Q1 2026.

• Research & Development for Q1 2026 came in at $321000.0, down 88.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 million (down 34.91% YoY), and the FY2025 annual result was $10.7 million, down 16.55% from the prior year.
• Research & Development came in at $321000.0 for Q1 2026 at Incannex Healthcare, down from $2.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $4.4 million in Q2 2024 to a low of $321000.0 in Q1 2026.
• The 5-year median for Research & Development is $2.4 million (2023), against an average of $2.3 million.
• Across the five-year window, Research & Development soared 154.61% in 2024 and plunged 88.26% in 2026, its largest moves.
• Incannex Healthcare's Research & Development stood at $1.5 million in 2022, then soared by 70.3% to $2.6 million in 2023, then tumbled by 46.4% to $1.4 million in 2024, then jumped by 61.24% to $2.3 million in 2025, then sank by 85.92% to $321000.0 in 2026.
• The last three Research & Development figures came in at $321000.0 (Q1 2026), $2.3 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.